J. Douglas

Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.

I. Blair, P. Carbone, A. Verma, 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma

G. Wilding, D. Alberti, K. M. Kim, 2006, Investigational New Drugs.

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

Howard Mackey, R. Burger, R. Wenham, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab in patients with advanced platinum-resistant ovarian cancer.

R. Burger, R. Wenham, S. Cannistra, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test

M. Ritter, G. Wilding, P. Hutson, 2008, Cancer Chemotherapy and Pharmacology.

Bioavailability Study of Oral Liquid and Tablet Forms of α-Difluoromethylornithine

P. Carbone, K. Tutsch, James P. Thomas, 2000 .

A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase

Michael S. Saag, George M. Shaw, J. Kappes, 1993 .

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Skin Cancer Prevention Study of α-Difluoromethylornithine in Subjects with Previous History of Skin Cancer

M. Pomplun, KyungMann Kim, P. Carbone, 2010, Cancer Prevention Research.

A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group.

J. Kappes, M. Saag, W. Schleif, 1993, The New England journal of medicine.

Study of common functional genetic polymorphisms of FCGR2A, 3A and 3B genes and the risk for cryptococcosis in HIV-uninfected patients.

S. Chanock, T. Walsh, D. Ennis, 2007, Medical mycology.

Phase I Chemoprevention Study of Piroxicam and rn

I. Blair, P. Carbone, A. Verma, 1998 .

Low-dose difluoromethylornithine and polyamine levels in human prostate tissue.

E. Messing, G. Wilding, R. Love, 1999, Journal of the National Cancer Institute.

Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.

P. Carbone, A. Verma, J. Pirsch, 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.